Identification of MAN1B1 as a Novel Marker for Bladder Cancer and Its Relationship with Immune Cell Infiltration

Table 1

Correlation between MAN1B1 expression with clinicopathologic features of BLCA.

Characteristic	Low expression of MAN1B1	High expression of MAN1B1
n	207	207
T stage, n (%)			0.121
T1	4 (1.1%)	1 (0.3%)
T2	65 (17.1%)	54 (14.2%)
T3	86 (22.6%)	110 (28.9%)
T4	32 (8.4%)	28 (7.4%)
N stage, n (%)			0.111
N0	126 (34.1%)	113 (30.5%)
N1	16 (4.3%)	30 (8.1%)
N2	42 (11.4%)	35 (9.5%)
N3	5 (1.4%)	3 (0.8%)
M stage, n (%)			0.336
M0	129 (60.6%)	73 (34.3%)
M1	5 (2.3%)	6 (2.8%)
Gender, n (%)			0.655
Female	52 (12.6%)	57 (13.8%)
Male	155 (37.4%)	150 (36.2%)
Age, n (%)			0.921
<=70	118 (28.5%)	116 (28%)
>70	89 (21.5%)	91 (22%)
Age, median (IQR)	69 (60, 76)	68 (60, 76)	0.880